SEARCH

SEARCH BY CITATION

References

  • Goodyear CS, O’Hanlon GM, Plomp JJ, Wagner ER, Morrison I, Veitch J, Cochrane L, Bullens RW, Molenaar PC, Conner J, Willison HJ (1999). Monoclonal antibodies raised against Guillain-Barre syndrome-associated Campylobacter jejuni lipopolysaccharides react with neuronal gangliosides and paralyze muscle-nerve preparations. J Clin Invest 6:697708.
  • Greenshields KN, Halstead SK, Zitman FM, Rinaldi S, Brennan KM, O’Leary C, Chamberlain LH, Easton A, Roxburgh J, Pediani J, Furukawa K, Furukawa K, Goodyear CS, Plomp JJ, Willison HJ (2009). The neuropathic potential of anti-GM1 autoantibodies is regulated by the local glycolipid environment in mice. J Clin Invest 3:595610.
  • Halstead SK, O’Hanlon GM, Humphreys PD, Morrison DB, Morgan BP, Todd AJ, Plomp JJ, Willison HJ (2004). Anti-disialoside antibodies kill perisynaptic Schwann cells and damage motor nerve terminals via membrane attack complex in a murine model of neuropathy. Brain 127:21092123.
  • Hillmen P, Young NS, Schubert J, Brodsky RA, Socie G, Muus P, Roth A, Szer J, Elebute MO, Nakamura R, Browne P, Risitano AM, Hill A, Schrezenmeier H, Fu CL, Maciejewski J, Rollins SA, Mojcik CF, Rother RP, Luzzatto L (2006). The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med 12:12331243.
  • Joint Task Force of the EFNS and the PNS (2006). European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of multifocal motor neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. J Peripher Nerv Syst 11:18.
  • Leger JM, Chassande B, Musset L, Meininger V, Bouche P, Baumann N (2001). Intravenous immunoglobulin therapy in multifocal motor neuropathy: a double-blind, placebo-controlled study. Brain 124:145153.
  • O’Hanlon GM, Humphreys PD, Goldman RS, Halstead SK, Bullens RW, Plomp JJ, Ushkaryov Y, Willison HJ (2003). Calpain inhibitors protect against axonal degeneration in a model of anti-ganglioside antibody-mediated motor nerve terminal injury. Brain 126:24972509.
  • Orbach H, Katz U, Sherer Y, Shoenfeld Y (2005). Intravenous immunoglobulin: adverse effects and safe administration. Clin Rev Allergy Immunol 3:173184.
  • Rother RP, Rollins SA, Mojcik CF, Brodsky RA, Bell L (2007). Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol 11:12561264.
  • Santoro M, Uncini A, Corbo M, Staugaitis SM, Thomas FP, Hays AP, Latov N (1992). Experimental conduction block induced by serum from a patient with anti-GM1 antibodies. Ann Neurol 4:385390.
  • Terenghi F, Cappellari A, Bersano A, Carpo M, Barbieri S, Nobile-Orazio E (2004). How long is IVIg effective in multifocal motor neuropathy? Neurology 4:666668.
  • van Schaik IN, Bossuyt PM, Brand A, Vermeulen M (1995). Diagnostic value of GM1 antibodies in motor neuron disorders and neuropathies: a meta-analysis. Neurology 8:15701577.
  • van Schaik IN, Bouche P, Illa I, Leger JM, Van den Bergh P, Cornblath DR, Evers EM, Hadden RD, Hughes RA, Koski CL, Nobile-Orazio E, Pollard J, Sommer C, van Doorn PA (2006). European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of multifocal motor neuropathy. Eur J Neurol 8:802808.
  • Willison HJ, Veitch J, Swan AV, Baumann N, Comi G, Gregson NA, Illa I, Zielasek J, Hughes RA (1999). Inter-laboratory validation of an ELISA for the determination of serum anti-ganglioside antibodies. Eur J Neurol 1:7177.
  • Yuki N, Yamada M, Koga M, Odaka M, Susuki K, Tagawa Y, Ueda S, Kasama T, Ohnishi A, Hayashi S, Takahashi H, Kamijo M, Hirata K (2001). Animal model of axonal Guillain-Barre syndrome induced by sensitization with GM1 ganglioside. Ann Neurol 6:712720.